-
The mTOR Inhibitor Rapamycin Attenuates Ozone-Induced Airway Inflammation and Emphysema In Mice
03 Feb 2026 15:28 GMT
… However, no mTOR-targeting drugs are currently approved for … that rapamycin treatment improved lung function and emphysema index, ameliorated … Alzheimer’s disease. Mol Pharmacol. 2014;85:441–450. … an emerging need for novel drug delivery systems. Chem Biol …
-
Wave Life Sciences Reclaims Rare Disease Drug From GSK, Targets Faster FDA Path
02 Feb 2026 19:21 GMT
… leads to severe, early-onset emphysema/COPD and liver … cohort of the RestorAATion-2 trial, which remains on track … U.S. Food and Drug Administration (FDA) on a potential accelerated … program to advance to a development candidate.
Under the collaboration, …
-
Mechanisms, Efficacy, Safety, and Pharmacoeconomics of Low-Dose, Long-Term Macrolide Antibiotics in the Treatment of Chronic Obstructive Pulmonary Disease: A Review
28 Jan 2026 17:26 GMT
… emphysema mice, attenuating emphysema … drug–drug interactions is recommended before medication … drugs with anti-inflammatory and immunomodulatory properties but no antibacterial activity.
Pharmacoeconomic … be developed. Treatment recommendations for …
-
Temple Health highlights new minimally invasive treatment option for emphysema
28 Jan 2026 04:55 GMT
A new minimally invasive treatment for emphysema was discussed in a recent … . Criner spoke about advancements in treating emphysema, a chronic lung condition that … available for those living with emphysema, emphasizing Temple Health’s commitment …
-
A Prognostic Nomogram Combining Radiologic Emphysema and Clinical Parameters in Small Cell Lung Cancer
27 Jan 2026 21:30 GMT
… Analysis and Model Development
Univariate Cox proportional hazards … strategies of treating all patients or treating none, … LDH, stage, treatment modality, and emphysema were significantly associated … lines reflect the “treat-all” and “treat-none” strategies, …
-
Philip Morris International Urges FDA Advisory Committee to Recommend Authorizing ZYN as a Modified Risk Tobacco Product
23 Jan 2026 14:44 GMT
… U.S. Food and Drug Administration’s (FDA) Tobacco Products Scientific Advisory … , heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” In their … invested over $14 billion to develop, scientifically substantiate and commercialize innovative …
-
Association Between Subsegmental Dosing Accuracy and Outcomes of Bronchoscopic Thermal Vapor Ablation: An Exploratory Retrospective Study in Severe Heterogeneous Emphysema
23 Jan 2026 05:57 GMT
… , Do Not Treat.
Statistics
Descriptive … pharmacological therapy, particularly in advanced emphysema, … Shanghai Hospital Development Center Foundation … treatment of severe emphysema with hyperinflation (RESET): a randomised controlled trial. Lancet Respir Med …
-
GSK kicks out of Wave's AATD programme
03 Feb 2026 13:31 GMT
… three years after the pharma group paid $170 million … consequence is life-threatening pulmonary emphysema, resulting in irreversible destruction … #47;2a RestorAATion-2 trial of the therapeutic in … but there are no treatments available for AATD liver disease …
-
HeartLung.AI Expands Preventive Imaging AI on Precision Imaging Network, part of Microsoft for Healthcare
03 Feb 2026 17:23 GMT
… from late-stage disease treatment to earlier identification … medical imaging.
HeartLung develops FDA-cleared AI technologies for … cardiovascular disease, lung cancer, emphysema/COPD, osteoporosis, … S. Food and Drug Administration (FDA) has approved the …
-
FDA Clears HeartLung's AI-CVD®, Enabling the Broadest Opportunistic Cardiovascular & Multisystem CT Screening Platform
12 Jan 2026 15:36 GMT
… from late-stage disease treatment to earlier identification … medical imaging.
HeartLung develops FDA-cleared AI technologies for … cardiovascular disease, lung cancer, emphysema/COPD, osteoporosis, … S. Food and Drug Administration (FDA) has approved the …
About
© 1995-2026